Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

New blood test pinpoints Parkinson's disease through mitochondrial DNA damage

Researchers have developed a new blood test that measures mitochondrial DNA damage as a potential marker for Parkinson's disease (PD). The study shows the test could aid in diagnosing PD and assessing responses to LRRK2 kinase inhibitors, which may help in reducing mitochondrial damage in PD patients.

4 Sep 2023

Combination of cediranib and lenalidomide does not improve outcomes in advanced thyroid cancer

Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) cediranib did not make a difference in outcomes for treating patients with an advanced form of thyroid cancer that develops from thyroid follicular cells called differentiated thyroid cancer (DTC).

1 Sep 2023

Parkinson's disease diagnosis could be made earlier with new blood test

Researchers have developed a blood test that detects Parkinson's disease, potentially establishing a way to help diagnose the condition before nervous system damage worsens.

30 Aug 2023

KIPA shows promise in predicting chemotherapy response in triple negative breast cancer

Researchers at Baylor College of Medicine and collaborating institutions are developing a strategy to predict the response of triple negative breast cancer (TNBC) to chemotherapy, which would be a valuable tool for physicians deciding on the treatment with better probability of success on an individual basis.

21 Jul 2023

$Fruquintinib improved survival in patients with refractory metastatic colorectal cancer$

Fruquintinib improved survival in patients with refractory metastatic colorectal cancer

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.

16 Jun 2023

New method can kill aggressive brain tumors

Researchers at the University of Gothenburg, working with French colleagues, have successfully developed a method able to kill the aggressive brain tumor glioblastoma.

25 May 2023

Anticoronavirals: the development of COVID-19 therapies and the challenges that remain

Researchers highlighted the pace of development of COVID-19 therapies during the pandemic and the challenges that hinder the widespread availability of anticoronavirals.

8 May 2023

Study investigates how loss of angulin-1/LSR affects the malignancy of lung adenocarcinoma

A new research paper was published in Oncotarget's Volume 14 on March 24, 2023, entitled, "Downregulation of angulin-1/LSR induces malignancy via upregulation of EGF-dependent claudin-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma A549 cells."

29 Mar 2023

One-Pot-LAMP: A promising tool for non-small cell lung cancer diagnosis

Researchers assessed the efficiency of a genetic decoding system for diagnosing non-small cell lung cancer (NSCLC).

16 Mar 2023

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma

Ipsen (Euronext: IPN; ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib.

From Ipsen 14 Feb 2023

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital, from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well as certain key shareholders and several managers and minority shareholders, following the entry into exclusive negotiations on June 30, 2022.

From Oncodesign Services 3 Feb 2023

Multiomics analysis of kidney metabolism reveals a gatekeeper for viral infections

Our kidney filters 180 liters of blood every day and retains nutrients through a process called 'endocytosis' and through active transport in the kidney cells.

2 Dec 2022

Updated EULAR recommendations on the use of DMARDs for people with RA

Since their first publication in 2010, the EULAR recommendations for the use of disease-modifying anti-rheumatic treatments (DMARDs) in people with RA have become a most important publication in the field, and their updates are relied upon by many healthcare professionals, professional organizations and other stakeholders to offer an up-to-date and robust analysis on an optimal approach to the application of available treatment options in clinical practice.

11 Nov 2022

Experimental cancer drug shows promise as a treatment for idiopathic pulmonary fibrosis

Researchers have shown that the medication saracatinib shows promise as a treatment for idiopathic pulmonary fibrosis (IPF).

13 Oct 2022

Signal transduction via the EGFR pathway likely to be involved in lenvatinib resistance

The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become resistant to lenvatinib remain poorly understood. In this study, we demonstrated, for the first time, that activation of the epidermal growth factor receptor (EGFR)-mediated signaling pathway is involved in lenvatinib resistance in thyroid cancer cells.

14 Sep 2022

$Fruquintinib provides survival benefits for patients with refractory metastatic colorectal cancer$

Fruquintinib provides survival benefits for patients with refractory metastatic colorectal cancer

13 Sep 2022

Triplet therapy slows progression of advanced kidney cancer

A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.

8 Sep 2022

Leukemia drug successfully disrupts HER2-positive brain metastasis in animal studies

In animal studies led by researchers at Duke Cancer Institute, a drug approved to treat leukemia successfully disrupted the ability of HER2-positive breast cancer tumors from colonizing the brain.

30 Aug 2022

New anti-cancer drug candidate is absorbed through the lymphatic system rather than blood vessels

A team of University of Michigan researchers is developing a new anti-cancer drug that is absorbed through the gut's lymphatic system rather than blood vessels, potentially outmaneuvering the molecular signaling pathways that lead to drug resistance while increasing cancer-fighting ability and reducing side effects.

17 Aug 2022

Pigment epithelium-derived factor ablations may lead to eye aging

Researchers identified that loss of pigment epithelium-derived factor (PEDF) may cause aging in the eye.

21 Jul 2022